CombiMatrix Announces Payor Contract with Fortified Provider Network
With the new contract, more than four million members across over 200 payor clients gain access to Combimatrix’s diagnostic solutions and clinical support.
Read MorePosted by Steve Halasey | Feb 24, 2015 | Molecular Diagnostics |
With the new contract, more than four million members across over 200 payor clients gain access to Combimatrix’s diagnostic solutions and clinical support.
Read MorePosted by Steve Halasey | Feb 24, 2015 | Research |
The Myeloma Prognostic Risk Signature will be used as en entry criterion for a Phase II trial of an investigational new drug to treat multiple myeloma patients.
Read MorePosted by Jenny Lower | Jan 14, 2015 | Emerging & Zoonotic Diseases, Infectious Diseases |
In the United States, efforts to combat ebola have focused on refining the standard operating procedures necessary to protect caregivers, including new standards for donning and doffing personal protective equipment.
Read MorePosted by Steve Halasey | Jan 12, 2015 | Research |
Under a new agreement, Interleukin Genetics will provide genetic profiling for a clinical trial evaluating Isis-APO(a)Rx for patients with high lipoprotein(a).
Read MorePosted by Jenny Lower | Jan 7, 2015 | Cancer, Molecular Diagnostics |
Advances in whole-genome sequencing technology such as copy-number assays are driving significant progress in the diagnosis and treatment of cancer.
Read More